Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Warner Music Group Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.46 (market cap $5.07B), while Warner Music Group Corp trades at $25.02 (market cap $13.12B). The key difference: Warner Music Group Corp is far larger — about 2.6× ACADIA Pharmaceuticals Inc.'s market cap, and Warner Music Group Corp pays a 3.19% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WMG | |
|---|---|---|
Market Cap | $5.07B | $13.12B |
Sector | Health | Media |
52-Week High | $29.41 | $34.72 |
52-Week Low | $20.06 | $23.65 |
Enterprise Value | $4.19B | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Warner Music Group (WMG) trades at $26.41, up 0.08% on the day, with a bearish technical signal but improving fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $7.3B projected for 2026. The stock shows a P/E of 20.06 and net income margin of 9.2%, supported by strong cash flow and dividend payments. Key resistance is at $27, with support at $26.
WMG presents a mixed outlook: bullish fundamentals with earnings beats and growth, but technicals indicate near-term pressure. Opportunities include streaming expansion and AI integration, while risks involve leadership changes and market volatility. Analyst consensus is 66.7% buy, suggesting long-term value if technical resistance is overcome.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
